Michele Cavo
Michele Cavo
Bortezomib (formerly PS-341) has been the first proteasome inhibitor to enter clinical trials in cancer patients. Preclinical studies showing that this novel agent directly inhibits the proliferation of myeloma cells, induces their apoptosi...
Shaji Kumar
Shaji Kumar
High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown to improve survival in patients with multiple myeloma in randomized trials and is the standard of care for eligible patients. Recent randomized trials su...
New approaches for the detection of minimal residual disease in acute myeloid leukemia [0.03%]
急性髓系白血病微小残留病检测的新方法
Anna van Rhenen,Bijan Moshaver,Gert J Ossenkoppele et al.
Anna van Rhenen et al.
The detection of minimal residual disease (MRD) in patients with acute leukemia has been studied for about 15 years by different groups in both the United States and Europe. It has been found that MRD detection can be performed using molecu...
What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia? [0.03%]
Gemtuzumab Ozogamicin在急性髓系白血病治疗中的作用是什么？
István Molnár,Bayard L Powell
István Molnár
Gemtuzumab ozogamicin (GO) is a novel, targeted chemotherapy designed to treat acute myeloid leukemia (AML). GO consists of an antitumor antibiotic, calicheamicin, linked to a humanized monoclonal antibody against CD33. It has been approved...
Antibiotic prophylaxis during chemotherapy-induced neutropenia for patients with acute leukemia [0.03%]
急性白血病患者化疗所致中性粒细胞减少期间的抗感染预防治疗
Sarah P Hammond,Lindsey R Baden
Sarah P Hammond
Chemotherapy-induced neutropenia places patients with acute leukemia at high risk for bacterial infections. A number of studies performed over the past 20 years have investigated the utility of prophylactic antimicrobials, including trimeth...
Richard E Clark
Richard E Clark
Several clinical observations demonstrate that immunologic effects are important in chronic myeloid leukemia (CML). The characteristic BCR-ABL fusion protein is a leukemia-specific antigen, and it has therefore received much immunologic att...
Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia [0.03%]
第二代酪氨酸激酶抑制剂在慢性髓性白血病治疗中的应用
Ronan Swords,Yesid Alvarado,Jorge Cortes et al.
Ronan Swords et al.
Chronic myeloid leukemia (CML) was the first human malignancy to be associated with a single genetic abnormality, characterized by a reciprocal translocation involving chromosomes 9 and 22 (the Philadelphia chromosome). The fusion gene that...
Sonja Burgstaller,Andreas Reiter,Nicholas C P Cross
Sonja Burgstaller
Constitutive activation of protein tyrosine kinases plays a central role in the pathogenesis of myeloproliferative disorders, including BCR-ABL-negative chronic myeloid leukemia. Current research is focused on elucidating the full spectrum ...
Genomic instability: The cause and effect of BCR/ABL tyrosine kinase [0.03%]
基因组不稳定及其诱发因素BCR/ABL酪氨酸激酶
Tomasz Skorski
Tomasz Skorski
Genes encoding c-ABL kinase and BCR protein are targeted by yet-unknown mechanisms causing DNA double-strand breaks resulting in the generation of a chimeric gene encoding BCR/ABL fusion tyrosine kinase. BCR/ABL kinase displays transforming...
Demetrios Petropoulos,Ka Wah Chan
Demetrios Petropoulos
Over the past decade umbilical cord blood has been established as a viable source of hematopoietic stem cells for allogeneic transplantation. Early experience with umbilical cord blood transplantation (CBT) demonstrated a lower incidence of...